Total Funding
79
69
Total FundingPost-IPO Equity raised
Growth Score 79 in past quarter
-17 pts
Heat Score 69 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
27918
iMDx is a biotech company helping save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer.
Rob Seitz: Head of Immune OncologyPast Role: Insight Genetics, Chief Technology Officer- Josh Riggs: President & Chief Executive OfficerPast Role: Intelliger Consulting, Founder & Principal
About the Company
iMDx is a molecular diagnostics company that develops and offers blood-based tests for oncology and transplant care. The company offers assays such as GraftAssureCore (a lab test for transplant rejection), GraftAssureIQ (a research-use kit), and DetermaIO for immunotherapy guidance. The company holds CLIA and state lab certifications.
Women Founded
